<DOC>
	<DOCNO>NCT00030732</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know gemcitabine effective without capecitabine treat pancreatic cancer . PURPOSE : Randomized phase III trial determine effectiveness gemcitabine without capecitabine treat patient advanced pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Capecitabine Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient advance pancreatic cancer treat gemcitabine without capecitabine . - Compare clinical benefit response , objective tumor response , duration response , time progression patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord metastasis ( yes v ) , pain ( yes v ) , Karnofsky performance status ( 60-80 % vs 90-100 % ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute day 1 8 oral capecitabine twice daily day 1-14 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . - Arm II : Patients initially receive gemcitabine IV 30 minute weekly 7 week . After 1 week rest , patient receive gemcitabine IV 30 minute weekly 3 week . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Quality life assess baseline , weekly week 2-7 , gemcitabine administration . Patients follow every 9 week . PROJECTED ACCRUAL : A total 300 patient ( 150 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary inoperable metastatic pancreatic adenocarcinoma No CNS metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10.0 g/dL Hepatic : Bilirubin great 5 time normal AST/ALT great 5 time normal Alkaline phosphatase great 5 time normal Renal : Creatinine clearance least 30 mL/min Gastrointestinal : No grade 2 great nausea grade 1 great vomit No medical condition would interfere take oral medication gastrointestinal absorption ( e.g. , small bowel obstruction ) Other : No prior unanticipated severe reaction fluoropyrimidine therapy No known hypersensitivity fluorouracil No known dihydropyrimidine dehydrogenase deficiency No active infection No serious concurrent systemic disorder would preclude study participation No malignancy within past 5 year except adequately treat carcinoma situ cervix basal cell skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior capecitabine No prior chemotherapy advanced pancreatic cancer At least 1 year since prior radiochemotherapy pancreatic cancer Endocrine therapy : Not specify Radiotherapy : See Chemotherapy At least 1 year since prior adjuvant radiotherapy pancreatic cancer No concurrent radiotherapy Surgery : Prior Whipple procedure duodenal bypass allow Other : At least 1 month since prior investigational agent No concurrent sorivudine chemically related analogue ( e.g. , brivudine ) No concurrent anticancer investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>